REBYOTA (fecal microbiota, live – jslm)
Prevention of recurrent C. difficile infection
ApprovedActive (Life-cycle management & real-world evidence)
Key Facts
Indication
Prevention of recurrent C. difficile infection
Phase
Approved
Status
Active (Life-cycle management & real-world evidence)
Company
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global, private biopharmaceutical company founded in 1950 and headquartered in Saint-Prex, Switzerland, with a significant operational presence in Prague, Czech Republic. The company focuses on high-need therapeutic areas, with a strong commercial portfolio and pipeline in reproductive medicine, uro-oncology, gastroenterology, and orthopaedics. Its recent strategic activities include label expansions for its gene therapy ADSTILADRIN, real-world evidence generation for its microbiome therapeutic REBYOTA, and entering into new clinical collaborations in bladder cancer.
View full company profile